A chimeric adenovirus with an Ad 3 fiber knob modification augments glioma virotherapy.
BACKGROUND
Malignant gliomas remain refractory to treatment despite advances in chemotherapy and surgical techniques. Viral vectors developed to treat gliomas have had low transduction capabilities, limiting their use. Gliomas over-express CD46, CD80, and CD86, all of which bind adenovirus serotype 3.


METHODS
To increase the infectivity and replication of oncolytic vectors in malignant brain tumors, we created a conditionally replicating adenovirus, CRAd-Survivin-5/3, which contains a survivin promoter-driving E1A and a chimeric fiber consisting of adenovirus serotype 3 knob.


RESULTS
In vitro, this modified CRAd showed ten- to 100-fold increased cytotoxicity against glioma cells. Ex vivo analysis of primary glioblastoma multiforme samples infected with CRAd-Survivin-5/3 showed an increase in cytotoxicity of 20-30% compared to adenovirus wild-type (AdWT). In normal human astrocytes and normal brain tissues, CRAd-Survivin-5/3 exhibited 30-40% and 10-15% lower cytotoxicity than AdWT, respectively. In an intracranial xenograft model of glioma, this oncolytic virus increased tumor-free survival and overall lifespan by 50% compared to controls (p < 0.05).


CONCLUSIONS
CRAd-Survivin-5/3 represents an attractive alternative to existing vectors and should be tested further in the pre-clinical setting.
Nandi
Suvobroto
S
The Brain Tumor Center, The University of Chicago, Chicago, IL, USA.
Ulasov
Ilya V
IV
Rolle
Cleo E
CE
Han
Yu
Y
Lesniak
Maciej S
MS
D000256:Adenoviridae / Q000235:genetics* / Q000378:metabolism; D001932:Brain Neoplasms / Q000378:metabolism / Q000628:therapy*; D045744:Cell Line, Tumor; D005822:Genetic Vectors / Q000235:genetics*; D005910:Glioma / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D008869:Microtubule-Associated Proteins / Q000235:genetics / Q000378:metabolism; D050130:Oncolytic Virotherapy / Q000379:methods*
D008869:Microtubule-Associated Proteins
Gene Ther. 2000 May;7(10):867-74
10845725
Cancer Res. 2008 Jul 15;68(14):5778-84
18632631
J Neurosurg. 2007 Sep;107(3):617-27
17886563
Expert Rev Neurother. 2006 Apr;6(4):479-88
16623647
Hum Gene Ther. 2005 Feb;16(2):209-22
15761261
Biochim Biophys Acta. 2008 Apr;1785(2):217-31
18328829
Mol Ther. 2008 Sep;16(9):1556-64
18665158
Curr Opin Mol Ther. 2008 Aug;10(4):371-9
18683102
Ann N Y Acad Sci. 2008 Oct;1142:108-32
18990124
Cancer Biol Ther. 2007 May;6(5):679-85
17404502
Surgery. 2005 May;137(5):527-35
15855925
J Gene Med. 2007 Mar;9(3):151-60
17351980
Mol Ther. 2004 Nov;10(5):958-66
15509513
J Cancer Res Clin Oncol. 2002 Jun;128(6):302-6
12073047
Hum Gene Ther. 2006 May;17(5):556-64
16716112
Neurosurg Rev. 2008 Apr;31(2):141-55; discussion 155
18259789
J Gen Virol. 1977 Jul;36(1):59-74
886304
J Neurosurg. 2006 Apr;104(4):583-92
16619663
Cancer Res. 1995 Nov 1;55(21):4752-6
7585498
N Engl J Med. 2005 Mar 10;352(10):987-96
15758009